更新于：2024-09-20
Ketotifen Fumarate
富马酸酮替芬
更新于：2024-09-20
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C23H23NO5S |
InChIKeyYNQQEYBLVYAWNX-WLHGVMLRSA-N |
CAS号34580-14-8 |
关联
31
项与 富马酸酮替芬 相关的临床试验A single-center, randomized, single-blind, controlled clinical trial of combined celecoxib with ketotifen fumarate to inhibit the recurrence of stiffness after release surgery for post-traumatic elbow stiffness
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)
Ketotifen in Non-Alcoholic Fatty Liver Disease Patients
100 项与 富马酸酮替芬 相关的临床结果
登录后查看更多信息
100 项与 富马酸酮替芬 相关的转化医学
登录后查看更多信息
100 项与 富马酸酮替芬 相关的专利（医药）
登录后查看更多信息
203
项与 富马酸酮替芬 相关的文献（医药）2023-11-24Medicine
Acute generalized exanthematous pustulosis caused by hydroxychloroquine in a patient with rheumatoid arthritis and CARD14 mutation: Case report
Article
作者: Ma, Wu-Kai ; Yao, Xue-Ming ; Luo, Feng ; Yuan, Xue-Mei ; Xiong, Hong ; Chen, Chang-Ming
Rationale::
Acute generalized exanthematous pustulosis (AGEP) is a serious adverse skin reaction characterized by the rapid appearance of densely distributed, small, sterile pustules with erythema. However, its pathogenesis is not fully understood. Hydroxychloroquine is widely used for the treatment of autoimmune diseases. Some patients presenting with AGEP have IL36RN and CARD14 gene mutations. Our report describes a patient with rheumatoid arthritis and AGEP associated with hydroxychloroquine and a newly discovered CARD14 gene mutation.
Patient concerns::
A 28-year-old woman with rheumatoid arthritis, treated with leflunomide therapy without marked relief of joint pain, developed multiple rashes with pruritis covering the body 5 days after switching to hydroxychloroquine treatment.
Diagnoses::
Based on the patient’s history, symptoms, and histopathological findings, AGEP was diagnosed.
Interventions::
Whole-exome sequencing and Sanger validation revealed no mutations in the IL36RN gene; however, a CARD14 gene mutation was present. The patient was treated using ketotifen fumarate tablets, dexamethasone sodium phosphate, calcium gluconate injection, methylprednisolone injection, vitamins C and B12, hydrocortisone butyrate cream, Reed acne cream, potassium chloride tablets, and pantoprazole enteric-coated capsules.
Outcomes::
The rash improved after 15 days.
Lessons subsections::
There has been little basic research on AGEP-related genetics, and the CARD14 mutation may underlie several pustular rashes, including AGEP and generalized pustular psoriasis. Follow-up studies and further accumulation of patient data are required.
2023-04-01Contact lens & anterior eye : the journal of the British Contact Lens Association
Determining initial ocular comfort differences between 0.7% olopatadine and 0.035% ketotifen fumarate
Article
作者: Kelley, Laurel R ; Pucker, Andrew D ; Logan, Amy ; Lievens, Chris ; Brafford, Randy ; McGwin, Gerald ; Christensen, Mike ; Franklin, Quentin ; Hogan, Catherine
PURPOSE:
To compare the ocular comfort at application of topical, over-the-counter, 0.7% olopatadine and 0.035% ketotifen fumarate anti-allergy eye drops.
METHODS:
This study recruited participants who were minimally symptomatic based upon Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire scores (≤3 units) and who had minimal between-eye inter-ocular comfort differences as judged by visual analog scale scores (VAS; ≤7 units). Baseline comfort was evaluated by eye with a VAS. One drop of 0.7% olopatadine or 0.035% ketotifen fumarate was then applied to the right eye with the alternative drop being immediately applied to the left eye. Participants were next evaluated with the same comfort VAS by eye at drop application, and then at 30 s, 1 min, and 2 min post-application. LogMAR visual acuities and bulbar conjunctival redness were evaluated pre- and post-drop application to judge initial changes.
RESULTS:
This study enrolled 159 participants who had a mean ± SD age of 26.3 ± 7.7 years, and 78.6% of the participants were female. The VAS found that the 0.7% olopatadine drop was more comfortable than the 0.035% ketotifen fumarate drop at all time-points. There were no between-eye differences in LogMAR visual acuities, yet bulbar redness was significantly less in 0.7% olopatadine treated eyes compared 0.035% ketotifen fumarate treated eyes.
CONCLUSION:
This study found that topically applied 0.7% olopatadine drops were initially more comfortable than 0.035% ketotifen fumarate drops.
2022-12-31Pharmaceutical biology
Network pharmacology-based analysis of the mechanism of
Saposhnikovia divaricata
for the treatment of type I allergy
Article
作者: Wang, Tingting ; Liu, Zhongcheng ; Zhang, Yanfen ; Li, Hui ; Li, Xiangsheng ; Zhao, Yang ; Sun, Yizhao ; Shao, Yuxin
CONTEXT:
Saposhnikovia divaricata (Turcz.) Schischk (Apiaceae) (SD) has various pharmacological activities, but its effects on type I allergy (TIA) have not been comprehensively studied.
OBJECTIVE:
This study evaluates the treatment and molecular mechanisms of SD against TIA.
MATERIALS AND METHODS:
The effective components and action targets of SD were screened using TCMSP database, and allergy-related targets of SD were predicted using GeneCards and OMIM database. The obtained target intersections were imported into David database for GO analysis, and used R software to perform KEGG analysis. The RBL-2H3 cells sensitised by DNP-IgE/DNP-BSA were treated with different concentrations of SD (root decoction, 0.5, 1, and 2 mg/mL), prim-O-glucosylcimifugin (POG, 10, 40, and 80 μg/mL) and the positive control drug-ketotifen fumarate (KF, 30 μM) for 12 h, then subjected to cell degranulation and qPCR analysis.
RESULTS:
Eighteen active compounds of SD and 38 intersection targets were obtained: TIA-related signal pathways mainly include calcium signal pathway, PI3K-Akt signal pathway and MAPK signal pathway. Taking the β-Hex release rate of the model group as the base, the release rate of SD and POG in high dose groups were 43.79% and 57.01%, respectively, which were significantly lower than model group (p < 0.01), and significantly lower than KF group (63.83%, p < 0.01, p < 0.05). SD and POG could down-regulate the expression of related proteins in the Lyn/Syk, PI3K/AKT and MAPK signalling pathways.
DISCUSSION AND CONCLUSION:
Saposhnikovia divaricata could inhibit IgE-induced degranulation of mast cells, providing a scientific basis for further research and clinical applications of SD in TIA treatment.
100 项与 富马酸酮替芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 皮炎 | 日本 | 1986-04-30 | |
| 湿疹 | 日本 | 1986-04-30 | |
| 瘙痒 | 日本 | 1986-04-30 | |
| 荨麻疹 | 日本 | 1986-04-30 | |
| 哮喘 | 瑞士 | 1979-05-03 | |
| 慢性荨麻疹 | 瑞士 | 1979-05-03 | |
| 变应性结膜炎 | 瑞士 | 1979-05-03 | |
| 特应性皮炎 | 瑞士 | 1979-05-03 | |
| 过敏性鼻炎 | 瑞士 | 1979-05-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 季节性过敏性结膜炎 | 临床3期 | 美国 | 2022-11-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | mucosal eosinophilia | 11 | Ketotifen 1 mg twice daily | 壓範窪蓋構衊遞窪艱積(鏇製顧積夢壓獵觸觸選) = Ketotifen was not superior to placebo with regard to global clinical response. Only 18% of patients demonstrated a complete or near-complete clinical response. 膚鏇廠膚襯範繭鏇鹽選 (遞蓋範餘製衊選餘鏇窪 ) | 不佳 | 2024-07-01 | |
N/A | 花生过敏 eosinophilia | 6 | 齋願齋蓋襯憲襯繭鹽網(餘糧顧願憲鹽鏇構窪蓋) = 3 anaphylactic reactions occurred: day-1 placebo patient at 50mg dose (gastrointestinal, cutaneous); day-5 treatment patient at 50mg dose, occurred post exercise, (gastrointestinal, cutaneous, respiratory); day-6 placebo patient at 12mg dose, associated with fever, (gastrointestinal, cutaneous, respiratory), epinephrine was given and patient withdrew from study 膚鑰網製願構糧築製窪 (鹽網網繭繭製餘廠廠齋 ) 更多 | 积极 | 2012-02-01 | ||
Placebo | |||||||
N/A | 99 | Epinastine HCl 0.05% | 齋選網膚糧艱齋願範願(獵繭蓋築選網廠願壓襯) = Three (5.9%) epinastine patients and 7 (14.6%) ketotifen patients experienced adverse events. Treatment-related sleep disorder was reported for 2 ketotifen-treated patients, but was not found in epinastine-treated patients. 憲壓鬱夢鹽齋構鹹選餘 (窪構窪膚繭壓鑰選範鬱 ) | - | 2004-05-01 | ||
N/A | 92 | 糧遞衊蓋製築鏇獵憲積(範憲鹹蓋糧鹽範襯製夢) = 糧廠積鹽選製築顧積艱 窪顧範範艱糧範醖獵願 (網鹹淵網範夢鬱範製衊 ) | - | 2003-05-01 | |||
Olopatadine HCl 0.1% | 糧遞衊蓋製築鏇獵憲積(範憲鹹蓋糧鹽範襯製夢) = 簾鹽遞廠願憲衊餘網築 窪顧範範艱糧範醖獵願 (網鹹淵網範夢鬱範製衊 ) | ||||||
N/A | 变应性结膜炎 HLA-DR+ | CD29+ | eotaxin+ | 19 | 鑰鹽積衊獵製獵願餘齋(窪顧獵鏇衊襯蓋獵憲襯) = 築壓壓窪壓醖觸衊網鹽 繭夢繭選糧顧製簾顧構 (鑰構窪選鏇築鏇願繭艱 ) 更多 | 积极 | 2003-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用